Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Peter Lau

Vascular Surgery Kansas City, MO Medical Doctor

NPI 1407276959 CMS profile 7226643

2750 Clay Edwards Dr Ste 304, Kansas City, MO 64116

Open in the dashboard

General payments

$22,879

225 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Peter Lau of Kansas City, MO is reported in the CMS Open Payments database as having received $22,879 across 225 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 83rd percentile of Vascular Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $5,135 53
2024 General $5,775 58
2023 General $2,031 32
2022 General $5,312 57
2021 General $1,450 14
2020 General $2,703 6
2019 General $474 5

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Peter Lau
  • Vascular Surgery median
  • Middle half of Vascular Surgery
  • National median

In program year 2025, general payments to Peter Lau were reported at $5,135. Among 3,991 Vascular Surgery profiles paid that year, the median was $924 and the middle half received between $273 and $2,636.

Show as a table
Year Peter Lau Vascular Surgery median Middle half National median
2019 $474 $796 $226–$2,363 $163
2020 $2,703 $348 $118–$1,110 $114
2021 $1,450 $471 $158–$1,421 $132
2022 $5,312 $725 $222–$2,183 $149
2023 $2,031 $836 $257–$2,440 $160
2024 $5,775 $909 $252–$2,619 $164
2025 $5,135 $924 $273–$2,636 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Endologix, Inc. $3,935 23 payments
  2. W. L. Gore & Associates, Inc. $3,513 34 payments
  3. Medtronic Vascular, Inc. $3,177 11 payments
  4. Medtronic, Inc. $2,550 32 payments
  5. Intuitive Surgical, Inc. $2,242 6 payments
  6. Penumbra, Inc. $1,517 16 payments
  7. AngioDynamics, Inc. $1,119 19 payments
  8. Silk Road Medical, Inc. $1,051 25 payments
  9. Abbott Laboratories $798 6 payments
  10. LeMaitre Vascular, Inc. $475 20 payments
  11. Other $2,501 33 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $16,389 209 payments
  2. Travel and Lodging $3,794 13 payments
  3. Grant $2,159 1 payment
  4. Education $537 2 payments
Products named General payments · program years 2019–2025
  1. Endurant $2,640 9 payments
  2. Da Vinci Surgical System $2,242 6 payments
  3. ENDURANT IIS $2,196 26 payments
  4. AFX2 Bifurcated Endograft System $1,291 8 payments
  5. ENDOCROSS Device $1,242 6 payments
  6. Torus Stent Graft System $1,242 6 payments
  7. AURYON LASER SYSTEM 100-120 VAC $1,119 19 payments
  8. GORE EXCLUDER Thoracoabdominal Branch Endoprosthesis $1,114 10 payments
  9. Alto Abdominal Stent Graft System $1,109 6 payments
  10. ENROUTE Transcarotid Stent $1,051 25 payments
  11. Other $11,328 150 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 8 drugs

Part D claims

310

Median for Vascular Surgery: 122

Drug cost

$29,570

Median for Vascular Surgery: $14,135

Branded share of claims

52.9%

Median for Vascular Surgery: 71%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 12 $13,559
Xarelto Rivaroxaban Brand 13 $11,317
Cilostazol Generic 98 $3,031
Clopidogrel Clopidogrel Bisulfate Brand 85 $1,060
Atorvastatin Calcium Generic 34 $284
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 35 $183
Cephalexin Generic 14 $69
Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim Brand 19 $65

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,087 Part D prescribers listed as Vascular Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 112 billing codes

Paid by Medicare

$200,141

Medicare's payments for the services billed

Medicare patients

459

Average age 75

Services billed

1,245

192 women, 267 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 53%
Diabetes 51%
Chronic kidney disease 49%
Arthritis 47%
Heart failure 37%
COPD 33%
Atrial fibrillation 30%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

225 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Vascular Surgery in Missouri

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record